Study of the blood–brain barrier-penetrating KRAS G12C inhibitor JMKX1899 in KRAS G12C-mutated NSCLC with brain metastases

Background: Patients with non-small cell lung cancer (NSCLC) harboring KRAS G12C mutations frequently develop brain metastases (BM). While KRAS G12C was once considered an undruggable target, the emergence of selective inhibitors has transformed it into a viable therapeutic option. However, effectiv...

Full description

Bibliographic Details

Published in:	Journal of the National Cancer Center
Main Authors:	Danming He, Yixiang Zhu, Jia Zhong, Hongqing Cai, Li Yuan, Wei Zhuang, Yan He, Xu Yang, Linjie Fan, Kailun Fei, Boyang Sun, Jie Zhao, Jinghong Xian, Xue Zhang, Zixiao Ma, Zhijie Wang, Jianchun Duan, Weimin Li, Hua Bai, Jie Wang
Format:	Article
Language:	English
Published:	Elsevier 2026-06-01
Subjects:	KRAS G12C mutation NSCLC Targeted therapy Brain metastases
Online Access:	http://www.sciencedirect.com/science/article/pii/S266700542500122X